Pernix Therapeutics to Report Q3 2014 Financial Results

MORRISTOWN, N.J.--(BUSINESS WIRE)--

Pernix Therapeutics Holdings, Inc. PTX, a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.

The conference call will feature remarks by Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer.

To participate in the conference call:

• Please dial (877) 312-8783 (domestic) or (408) 940-3874 (international).
• Participants can reference the passcode 14525070.

Please dial in approximately 15 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company's website www.pernixtx.com. The press release, financial highlights and presentation slides will be posted in this section prior to the call.

An online archive of the webcast will be available on the Company's website for 30 days following the call.

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on developing and commercializing innovative products. The Company currently focuses its promotional efforts in the area of CNS, including neurology and psychiatry, and has an interest in expanding its portfolio into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The company's core strengths include the acquisition, development, sales and marketing of specialty products.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.